Advancements and Possibilities for the Treatment of Idiopathic Inflammatory Myopathies

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 455

Special Issue Editors


E-Mail Website
Guest Editor
Faculdade de Medicina,Universidade Federal do Cariri–UFCA, Juazeiro do Norte, Brazil
Interests: polymyositis; dermatomyositis; anti-synthetase syndrome; inflammatory myopathy; immune-mediated necrotizing myopathy; inclusion body myositis; mental health; multidisciplinary approach

E-Mail Website
Guest Editor
Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Interests: polymyositis; dermatomyositis; anti-synthetase syndrome; immune-mediated necrotizing myopathy; inclusion body myositis; inflammatory myopathy; treatment

Special Issue Information

Dear Colleagues,

With the advances in our knowledge on immunology and rheumatology, the prospects for therapeutic targets in the treatment of idiopathic inflammatory myopathies (IIMs) have evolved.

Therefore, we invite the academic community to contribute high-impact and clinically relevant papers to this Special Issue, which will showcase advances in the treatment of IIMs:

  • New therapeutic targets for IIM treatment—molecular mechanisms and perspectives;
  • Approaches to skin manifestations in IIMs;
  • Therapeutic perspectives in the treatment of interstitial lung disease-associated IIMs;
  • Treatment of calcinosis in IIMs;
  • Treatment of fatigue in IIMs;
  • Dysphagia management in IIMs;
  • Osteometabolism and IIMs;
  • Mapping of side effects and the treatment of infections;
  • Rehabilitation of IIM patients;
  • Autoantibody profiles, phenotypic characterization, and therapeutic response in IIMs—perspectives and potential;
  • Advances and practical contributions regarding the use of images in the treatment of IIMs;
  • Particularities, advances, and challenges in the treatment of juvenile idiopathic inflammatory myopathies;
  • Phenotypic characterizations of IIMs and their therapeutic particularities;
  • Muscle biopsy as a tool in managing cases and adjusting treatment in IIMs.

Dr. Jucier Gonçalves Júnior
Dr. Samuel Katsuyuki Shinjo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anti-synthetase syndrome
  • dermatomyositis
  • polymyositis
  • inflammatory myopathy
  • myositis
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

12 pages, 354 KB  
Systematic Review
Is Hydroxychloroquine Useful for the Treatment of Cutaneous Manifestations of Idiopathic Inflammatory Myopathies? A Systematic Review
by Jucier Gonçalves Júnior, Jamily Izabel Alves dos Santos and Samuel Katsuyuki Shinjo
Pharmaceuticals 2025, 18(9), 1293; https://doi.org/10.3390/ph18091293 - 29 Aug 2025
Viewed by 219
Abstract
Background/Objectives: Hydroxychloroquine (HCQ) is frequently used to manage cutaneous manifestations associated with idiopathic inflammatory myopathies (IIMs). Nevertheless, the literature lacks consensus regarding the efficacy and safety of drugs for these manifestations. Methods: A systematic literature review was conducted in accordance with [...] Read more.
Background/Objectives: Hydroxychloroquine (HCQ) is frequently used to manage cutaneous manifestations associated with idiopathic inflammatory myopathies (IIMs). Nevertheless, the literature lacks consensus regarding the efficacy and safety of drugs for these manifestations. Methods: A systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. The search spanned the period from January 1958 to April 2025 across the following databases: PubMed, Scopus, Web of Science, Cochrane Library, PsycInfo, and Virtual Health Library. Articles were included if they contained at least one of the specified descriptors in the title or abstract; were published in English, Portuguese, or Spanish; and addressed the use of HCQ or chloroquine (CQ) in the context of skin manifestations of IIMs. Review articles, experimental studies, and short communication articles were excluded. Results: Among the 319 patients assessed, the majority were women diagnosed with dermatomyositis or juvenile dermatomyositis. The most prevalent cutaneous manifestations were Gottron’s papules and diffuse erythematous lesions. The most frequent extracutaneous manifestations were muscle weakness and arthritis/arthralgia. HCQ was administered in 74% of the cases, with dosages ranging from 200 to 400 mg/day and a follow-up duration of 26 months. In most cases, it is administered in conjunction with glucocorticoids. Adverse effects were observed in less than 9% of the patients, with myalgia, skin lesions, and photosensitivity being the most common. However, the use of CQ has not been documented in any of these studies. Conclusions: Although there are studies in the literature using HCQ as part of the treatment of cutaneous manifestations in patients with IIMs, longitudinal studies with larger sample sizes and more robust methods are required to evaluate the applicability of HCQ in the treatment of IIMs. Full article
Show Figures

Figure 1

Back to TopTop